

Sterne Kessler Scores \$83.4M Federal Jury Verdict for TwinStrand Biosciences, Inc.

A Sterne, Kessler, Goldstein and Fox litigation team represented TwinStrand Biosciences, Inc. and the University of Washington in a federal patent infringement case against Guardant Health. On November 14, 2023, the jury awarded \$83.4 million in past damages, and also found that Guardant Health willfully infringed the two asserted patents by the sale of Guardant's FDA-approved Guardant 360 CDx product, as well as all of its other commercial products in cancer screening, detection, and characterization. The patents at issue were U.S. Patent No. 10,760,127 and U.S. Patent No. 10,287,631, both owned by the University of Washington and exclusively licensed to TwinStrand Biosciences. TwinStrand was founded by the inventors of the patents.

The Sterne Kessler trial team was led by Directors [Byron L. Pickard](#) and [R. Wilson "Trey" Powers III](#) and included fellow Directors [Chandrika Vira](#), [William H. Milliken](#), [Anna G. Phillips](#) and [Tyler J. Dutton](#), along with Counsel, [Christopher M. Gallo](#) and Associates [Matthew M. Zuziak](#), [Brady P. Gleason](#), [Louis P. Panzica](#), [Ryan N. Kaiser](#), [Jamie Dohopolski](#), and [John Hylton](#).

A press release issued by TwinStrand details the case and is posted [here](#). The jury verdict is available [here](#).

Sterne Kessler also successfully handled several related matters on behalf of TwinStrand at the US Patent Trial and Appeal Board (PTAB) upholding the validity of all challenged claims. Coverage of the cases is available [here](#).

Media Contact

Kathryn Holmes Johnson
Director of Communications
+1 202.772.8925
kholmesjohnson@sternekessler.com